Key Highlights
- Compass Pathways shares climbed +30.18% in pre-market hours, hitting $13.50
- First-quarter adjusted loss per share of -$0.30 exceeded Wall Street’s -$0.43 forecast
- FDA accepted rolling NDA submission and review process for COMP360 psilocybin treatment
- Company received Commissioner’s National Priority Voucher, which may accelerate regulatory timelines by one to two months
- Wall Street analysts upgraded price targets, with consensus recommendation at “Strong Buy” among 11 firms
Compass Pathways experienced a remarkable Monday morning. The UK-based biotechnology firm saw its shares surge over 30% in pre-market trading to $13.50 — eclipsing its previous 52-week peak of $11.28 — following a confluence of positive developments announced over the weekend.
The dramatic share price movement stemmed from a triple combination of catalysts: better-than-anticipated quarterly results, a significant FDA regulatory advancement, and the award of an uncommon expedited review voucher.
Regarding financial performance, Compass disclosed first-quarter adjusted earnings per share of -$0.30, surpassing the Street’s consensus forecast of -$0.43. While still representing a loss, such meaningful outperformance carries weight for clinical-stage biotechnology companies.
The more substantial development came from the regulatory arena. The Food and Drug Administration approved Compass for a rolling New Drug Application submission and review mechanism for COMP360, the company’s synthetic psilocybin formulation designed to treat treatment-resistant depression. This rolling review process has already commenced.
Additionally, Compass obtained a Commissioner’s National Priority Voucher. This special designation has the potential to reduce FDA review periods by approximately one to two months — a significant timeline compression for a company approaching commercialization.
The company has already filed at least one of three required NDA modules. Management continues to target Q4 2026 for complete NDA submission, with preparations for commercial launch anticipated to conclude by year-end.
Wall Street Raises Targets
The investment community reacted swiftly to the news. TD Cowen confirmed its Buy recommendation. RBC Capital Markets increased its price objective to $22 from $21, maintaining its Outperform stance while highlighting supportive regulatory dynamics and robust clinical data. Maxim Group delivered the most aggressive revision, elevating its target to $20 from $12. Morgan Stanley adjusted upward to $17 from $16 while keeping its Overweight rating intact.
Among 11 covering analysts, CMPS carries an average “Strong Buy” recommendation.
The regulatory landscape received additional support from a recent White House executive directive instructing the Drug Enforcement Administration to expedite rescheduling evaluations for psychedelic compounds that have successfully completed Phase 3 clinical trials. Current guidelines permit DEA rescheduling reviews to proceed concurrently with FDA assessments.
Compass anticipates COMP360 will initially receive Schedule 2 classification, with official rescheduling potentially finalized within days of FDA approval — a timeframe that alleviates some regulatory uncertainty that has historically pressured the psychedelic medicine sector.
COMP360 Pipeline Outlook
Part B results from the COMP006 Phase 3 clinical trial are scheduled for early Q3 2026. This data release will attract significant investor attention.
Compass concluded the quarter with $466 million in cash and cash equivalents, providing operating runway extending into 2028. This substantial cash position eliminates near-term capital-raising concerns.
Notably, Monday’s broader market context was unfavorable — both the S&P 500 and Nasdaq Composite traded lower. The CMPS rally was driven purely by company-specific catalysts.
The biotechnology firm is also slated to present at an upcoming investor conference, which could maintain institutional investor engagement in coming weeks.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
